# US 2018/0021313 A1 · Methazolamide for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021313 A1
- Document ID: US20180021313A1
- Status: Published application
- Kind: A1
- Application number: 15/651,060
- Filed: 2017-07-17
- Published: 2018-01-25
- Earliest claimed: 2016-07-21
- Assignees: Cipla Limited
- Applicants: Cipla Limited
- Inventors: Geena Malhotra; Kalpana Joshi; Jeevan Ghosalkar
- Web page: https://patentgrep.com/patent/US20180021313A1

## CPC

- A61K 31/433: Thidiazoles
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods of using methazolamide to treat pancreatic cancer. Pancreatic cancer can be treated by administering to a patient in need thereof an effective amount of methazolamide, optionally in combination with one or more additional cancer therapies.

## Claims

### Claim 1

A method of treating pancreatic cancer comprising administering to a patient in need thereof an effective amount of methazolamide or a pharmaceutically acceptable derivative thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the pancreatic cancer is Stage 0, Stage IA, Stage IB, Stage IIA, Stage IIB, Stage III, or Stage IV.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising administering at least one other cancer therapy.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the additional cancer therapy comprises surgery, chemotherapy, immunotherapy, ablation, embolization, or ionizing radiation.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the additional cancer therapy comprises administering at least one additional chemotherapeutic agent comprising a nucleoside analog, antifolate, antimetabolite, topoisomerase I inhibitor, anthracycline, podophyllotoxin, taxanes, vinca alkaloid, alkylating agent, platinum compound, proteasome inhibitor, nitrogen mustard, oestrogen analogue, monoclonal antibody, tyrosine kinase inhibitor, mTOR inhibitor, retinoid, immunomodulatory agent, histone deacetylase inhibitor, or other kinase inhibitor.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the additional chemotherapeutic agent comprises a nucleoside analog.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the additional chemotherapeutic agent comprises gemcitabine, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the additional cancer therapy comprises treatment with ionizing radiation.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the additional cancer therapy comprises surgery.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the patient has not been previously treated for pancreatic cancer.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the patient has undergone at least one prior treatment for pancreatic cancer.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the methazolamide is administered orally.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the methazolamide is administered in an amount from 50-500 mg/day.

### Claim 14

A pharmaceutical composition comprising methazolamide and at least one other anti-cancer drug.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the anti-cancer drug is a nucleoside analog.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the anti-cancer drug is gemcitabine, or a pharmaceutically acceptable salt thereof.

### Claim 17

A kit comprising methazolamide and instructions for a dosing regimen effective to treat pancreatic cancer.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the kit further comprises at least one other anti-cancer drug.

### Claim 19 (depends on 18)

The kit of claim 18, wherein the anti-cancer drug is gemcitabine.
